The researchers from the United States have developed a coronavirus vaccine based on the SARS-COV-2 S-COV S-COV-2 domain, and during the mice studies, the most effective adjuvants for it are aluminum hydroxide and CPG protein. The new drug has shown efficiency similar to MRNAV-vaccines and, according to researchers, whose article was published in the Journal Science Translational Medicine, designed primarily for the elderly.
“RBD is the key target of vaccines against SARS-COV-2, but the RBD protein itself has a weak immunogenicity. That is why (in other vaccines – approx.” Tape.ru “) used full S-protein, which is more difficult to massively produce, “- explains the lead author of David Dauling from Harvard Medical School. In order to choose the best adjuvants – substances that increase the effect of vaccines – researchers tested their various combinations with a vaccine on young mice. Doses were administered to rodents and their humoral was measured – the immune response associated with antibodies – the immune response.
“We found that a successful RBD combination with two adjuvants – aluminum hydroxide and (image-recognizing receptor – approx.” Tape.ru “) CPG. It was equivalent, and in some cases exceeded existing MRNA-vaccines,” – noted one of the scientists Esuro Nanishi. Aluminum hydroxide is the most common Ajuvant in the world, it helps the vaccine antigens longer to hold in the body. CPG is known for stimulating tall-like receptors of a congenital immune system, thereby causing a stronger immune response.
In the course of experiments, the mixture has activated a congenital immune response in the leukocytes of older people, similar to that of younger people. After the mixture is administered to mice, the high titer of neutralizing antibodies was recorded in all age groups. Adjuvant vaccine completely defended the old age in 14 months – mice from SARS-COV-2 infection. The developers emphasize that their drug – unlike mRNA-vaccines – does not need a cold chain.